Search

In a phase 2 trial evaluating healthy donor fecal microbial transplantation plus either anti-PD-1 in patients with non-small cell lung cancer or anti-PD-1 and anti-CTLA-4 in patients with melanoma, encouraging efficacy was seen in both cohorts, with responses linked to significantly greater loss of baseline bacterial species.

In this multicenter phase 1 trial of patients with advanced solid tumors resistant to anti-PD-1 therapy, treatment with the anti-latent TGFβ1 antibody linavonkibart with or without pembrolizumab was safe, and encouraging clinical response rates were associated with T cell infiltration and immune activation.

Five-year follow-up and prespecified exploratory biomarker analysis from the phase 3 KEYNOTE-426 trial show that pembrolizumab plus axitinib compared to sunitinib as first-line therapy continues to show overall and progression-free survival benefits in patients with advanced clear cell renal cell carcinoma and indicate that a T-cell-inflamed gene expression profile is predictive of response.

Exportin-1 (XPO-1) inhibitor selinexor has been reported as a therapeutic option in solid cancer. Here, the authors present a phase 1 clinical trial combining selinexor with chemotherapy by gemcitabine in patients with advanced sarcoma.

The durability of Fe-N-C single-atom-catalysts for oxygen reduction in acidic medium remains elusive. Here, the authors report how a low amount of platinum stabilizes the FeN4 sites via a long-range electronic effect.

Borcoman and colleagues present the efficacy and safety results of the phase 2 PEVOsq basket trial investigating the combination of pembrolizumab with the epidrug vorinostat in patients with recurrent and/or metastatic squamous cell carcinoma.

Electrosynthesis of hydrogen peroxide offers a cleaner, cost-effective alternative to anthraquinone processes. Here the authors report oxygen-deficient perovskite oxides with rich oxygen vacancies as bifunctional catalysts for concurrent oxygen reduction and water oxidation reactions in scalable hydrogen peroxide electrosynthesis.

There is a lack of effective therapies for patients with non-V600E BRAF mutant cancer. Here, the authors report limited response in a phase II trial investigating the combination of binimetinib (MEK inhibitor) and encorafenib (BRAF inhibitor) for the treatment of non-V600E BRAF mutant cancer and subsequently investigate resistance mechanisms and combination therapeutic strategies in patient-derived models.

In the proof-of-concept phase 2 ROME trial, comprehensive genomic profiling followed by molecular tumor board evaluation and randomization of patients with metastatic solid cancer to receive personalized therapy or standard of care led to a significantly higher objective response rate and longer progression-free survival in patients who received personalized therapy.

In this single-arm phase 2 trial in patients with HR⁺HER2⁻ advanced breast cancer, treatment with the HER3-targeting antibody–drug conjugate paritumab deruxtecan led to encouraging objective response rates, and comprehensive exploratory analyses indicate potential biomarkers of response.

The widespread use of fuel cells requires improved catalysts to reduce oxygen efficiently at the cathode. It is shown that model, well-characterized size-selected Pt_xY nanoparticles can be synthesized by the gas aggregation technique, and that they are highly active for this reaction.

Defective platinum diselenide can serve as a highly efficient and stable catalyst for the oxygen reduction reaction outperforming commercial Pt/C catalysts, which is achieved by a restructuring approach via electrochemical cycling.

PARP inhibitors, either alone or in combination with bevacizumab, have regulatory approval as maintenance therapy following response to first-line platinum-based chemotherapy. Here this group reports SOLACE2 trial investigating whether combining olaparib with low dose cyclophosphamide treatment improves progression-free survival, comparing to olaparib monotherapy alone, in platinum-sensitive recurrent ovarian cancer.

Therapeutic options for patients with renal medullary carcinoma (RMC) are limited. Here the authors report the results of a phase II clinical trial of anti-PD1 nivolumab plus anti-CTLA4 ipilimumab in RMC, associating the activation of a myeloid mimicry program in tumor cells to the rapid disease progression and hyper-progression observed in treated patients.

Improvements in the activity and stability of catalysts for oxygen reduction reactions are needed to make low-temperature, polymer electrolyte membrane fuel-cells viable for mobile applications. Pt₃Sc and Pt₃Y are shown experimentally to have greater catalytic activity than pure Pt after being identified through computational investigation of Pt- and Pd-based alloys.

Single-atom catalysts consisting of isolated iron sites on a nitrogen-doped carbon matrix (Fe–N–C) are very promising cathode catalysts for proton exchange membrane fuel cells (PEMFC), but it is challenging to achieve a high density of single iron sites. Now, a synthetic approach is introduced to afford high-density Fe–N–C catalysts with a high PEMFC performance.

Electrocatalysts which deliver high selectivity for two-electron oxygen reduction to hydrogen peroxide in acidic media are sought to replace the conventional anthraquinone process. Here, the authors develop partially oxidised palladium clusters on carbon nanotubes with near 100% selectivity.

Enhancing and optimizing the performance and durability of nanocatalysts for the oxygen reduction reaction is crucial for fuel-cell applications. A class of Pt–Co nanocatalysts consisting of ordered Pt₃Co intermetallic cores with a 2–3 atomic-layer-thick platinum shell now exhibit a large increase in mass activity and specific activity when compared with disordered alloy nanoparticles.

The synthesis of high concentration H₂O₂ from water and oxygen at moderate conditions could provide an on-site H₂O₂ source for medical and water purification applications. Here, authors show Al₂O₃-stabilized PtP₂ nanocrystals to enable selective, stable and efficient neutral pH H₂O₂ production.

Results of the phase 1/2 TACTOPS trial show that autologous T cell therapy targeting PRAME, SSX2, MAGEA4, Survivin and NY-ESO-1 in patients with pancreatic ductal adenocarcinoma is feasible and safe, and leads to encouraging clinical responses and evidence of antigen spreading in responders.

As presented at the ESMO Congress 2025: In patients with locally advanced or metastatic solid tumours, including mesothelioma, treatment with a first-in-class inhibitor of the Hippo−YAP−TEAD pathway was safe and led to encouraging clinical response rates in patients with mesothelioma.

Platinum group metal- and iron-free catalysts are highly desirable for the oxygen reduction reaction in proton-exchange membrane fuel cells. Now, Wu and co-workers show a carbon catalyst with atomically dispersed single Mn sites as an efficient catalyst with enhanced stability in acidic media.

Iron- and nitrogen-doped carbon materials are effective catalysts for the oxygen reduction reaction whose active sites are poorly understood. Here, the authors establish a new pyridinic iron macrocycle complex as a more effective active site model relative to legacy pyrrolic model complexes.

Immune checkpoint inhibitors have been incorporated as the standard of care for some high-grade neuroendocrine neoplasms (NEN), but their efficacy in digestive NEN is still unclear. Here the authors report the results of a phase II trial of nivolumab (anti-PD1) in combination with platinum-doublet chemotherapy (carboplatin-etoposide) as first-line treatment in patients with unresectable or metastatic advanced grade 3 NENs of gastro-enteropancreatic or unknown origin.

This Review outlines the fundamental role of chimeric antigen receptor (CAR) T cell therapy for children, adolescents and young adults (CAYAs) with relapsed and/or refractory B cell acute lymphoblastic leukaemia, emphasizing the crucial need to further exploit CAR T cells and other immunotherapies to improve survival with broadened access across disease states. Opportunities and challenges for expanding CAR T cell therapy to other haematological and non-haematological malignancies in CAYAs are also discussed.

HER3 is emerging as a promising therapeutic target that is often overexpressed or genetically altered across diverse solid tumour types. This Review describes the landscape of HER3 alterations in cancer and their prognostic implications, the roles of HER3 in oncogenesis and resistance to targeted therapies, and the ongoing clinical development of agents targeting HER3.

An in-depth analysis of tissue biopsies from patients with multiple myeloma and CAR T cell therapy-associated immune-related adverse events (CirAEs) after treatment with commercial BCMA-targeted CAR T cell therapy shows that CD4⁺ CAR T cells mediate off-tumor toxicities and that high CD4:CD8 ratio at apheresis, robust early CAR T cell expansion, ICANS and ciltacabtagene autoleuce treatment are independently associated with the development of CirAEs.

As presented at the 2025 AACR Annual Meeting, in an ongoing first-in-human phase 1 trial of a next-generation KRAS-G12C inhibitor in patients with solid tumors, encouraging safety and response results were observed, including in patients with non-small-cell lung cancer.

Nitrogen-doped carbon materials with atomically dispersed iron or cobalt are promising for catalytic use. Here, the authors show that cobalt moieties have a higher redox potential, bind oxygen more weakly and are less active toward oxygen reduction than their iron counterpart, despite similar coordination.

Replacement of platinum is important for lowering the cost of fuel-cell electrocatalysts, but less precious alternatives such as palladium are hindered by lower durability. Here, the authors show that incorporation of trace amounts of gold improves the durability of palladium based oxygen reduction catalysts.

Roussos-Torres and colleagues perform a phase Ib clinical trial of entinostat, nivolumab and ipilimumab in individuals with advanced HER2-negative breast cancer, report on safety and response and characterize the immune-modulatory effects.

The identification of biomarkers of response to PARP inhibitors can enable selection of appropriate ovarian cancer patients for treatment. In this study, the authors report clinical results and exploratory biomarker analyses from the ARIEL2 phase 2 clinical trial on the safety and efficacy of the PARP inhibitor rucaparib in patients with recurrent ovarian cancers

Results from this single-arm cohort of the BFAST trial showed that the clinical efficacy of entrectinib in patients with ROS1-positive NSCLC, selected using liquid biopsies, is consistent with that seen in previous reports where patients were selected using tissue-based testing methods.

Alterations in the tumour suppressor genes STK11 and/or KEAP1 can identify patients with advanced non-small-cell lung cancer who are likely to benefit from combinations of PD-(L)1 and CTLA4 immune checkpoint inhibitors added to chemotherapy.

The interaction between the carbon support, active sites, and ionomer is crucial for oxygen reduction reaction catalysts. In this study, the authors employed operando X-ray Absorption Spectroscopy to demonstrate that mesoporous carbon supports facilitate optimal ionomer-catalyst interactions, enhancing catalyst performance.

HER2 amplification in metastatic colorectal cancer (mCRC) identifies a group of patients with poorer prognosis. Here, the authors report the results of a phase II clinical trial assessing the clinical response and safety of trastuzumab deruxtecan as a third-line treatment in patients with mCRC with different HER2 expression levels

In the final analysis of all cohorts in the phase 2 ROAR basket trial, dabrafenib plus trametinib exhibited tumor-agnostic clinical activity in patients with rare BRAFV800E-mutated cancers, including anaplastic thyroid carcinoma, biliary tract cancer, low-grade glioma and hairy cell leukemia.

In this phase 1 trial, treatment of patients with fibrolamellar hepatocellular carcinoma with a therapeutic peptide vaccine targeting the fusion kinase DNAJB1–PRKACA, which is the driver of the disease, together with nivolumab and ipilimumab, was safe and led to encouraging preliminary clinical responses, and translational analysis showed activation of immune responses.

The randomized B-F1RST trial evaluating the clinical utility of blood tumor mutational burden as a predictor of benefit from atezolizumab in patients with advanced lung cancer did not meet its pre-specified primary objective, underscoring the need to further investigate the significance of bTMB as a relevant biomarker for patient selection.

A high oxygen reduction reaction activity can usually be realized by increasing platinum specific activity at the expense of active surface area. Self-supported platinum–cobalt-oxide networks combining high activity and surface area now promise a stable fuel-cell operation.

For oxygen reduction and hydrogen oxidation reactions, proton-exchange membrane fuel cells typically rely on precious-metal-based catalysts. A p-block single-metal-site tin/nitrogen-doped carbon is shown to exhibit promising electrocatalytic and fuel cell performance.

In an ongoing phase 1 trial, the combination of two new immunotherapies targeting CTLA-4 and PD-1 was overall well tolerated and elicited encouraging clinical responses in patients with relapsed/refractory microsatellite stable colorectal cancer, a tumor type typically unresponsive to immune checkpoint blockade.

Treatment of patients with relapsed or refractory multiple myeloma with a combination of the BCMA-targeting antibody–drug conjugate belatamab mafodotin with dexamethasone and pomlidomide is safe and shows promising preliminary clinical efficacy.

Although Fe–N–C materials are promising catalysts for oxygen electroreduction in polymer fuel cells, the structure of their active sites is unclear. Quantitative analysis of Fe–N–C now reveals the existence of porphyrin-like FeN₄C₁₂ moieties.

Deployment of proton-exchange membrane fuel cells is limited by the durability of Pt-nanoscale catalysts during cathodic oxygen reduction reactions. Dissolution processes on single crystalline and thin film surfaces are now correlated leading to the design of PtAu catalysts with suppressed dissolution.

The electrosynthesis of H₂O₂ is a potential alternative to the traditional, energy-intensive anthraquinone process. This Review describes the electrochemical production of H₂O₂ using membrane electrode assembly (MEA) cells and examines core components, different MEA configurations, alternative anode oxidation reactions and cascade catalytic systems.

The activity of PD-1 blockade in patients with sarcoma has been modest so far. Here, the authors report the results of a pilot clinical trial to assess the efficacy and safety of bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, in combination with the PD1 blockade (nivolumab) in patients with locally advanced or metastatic high-grade sarcoma.

There is a need for potent and non-toxic estrogen receptor (ER) antagonists to overcome the limitations of existing endocrine therapies. Here the authors report the results from Arm 1 of the Phase 1/2 study (AMEERA-1) among postmenopausal women with ER+/HER2− advanced breast cancer, which evaluates the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of amcenestrant administered as monotherapy.

In a prespecified interim analysis of a pivotal phase 2 trial, avapritinib, a selective KIT inhibitor, elicited robust clinical and molecular responses, was generally well tolerated and led to improved patient-reported outcomes in patients with advanced systemic mastocytosis.